Rockville, MD, United States, February 22, 2024 – Advanced BioScience Laboratories, Inc. (ABL), a global Contract Development and Manufacturing Organization (CDMO) and a Contract Research Organization (CRO) to the U.S. Government and biopharmaceutical industry announced that it has been awarded a  three-year Task Order to provide ‘Preclinical Testing of Site-Blocking Oligonucleotides’ under the IDIQ contract for “Manufacturing and Nonclinical Studies support for Development of Therapeutic Biotechnology Products (Biologics) for Neurological-related Disorders” by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).

The objective of this Task Order is to support the NINDS’ BPN (Blueprint)-Biologics cooperative agreement work by manufacturing candidate steric-block oligonucleotides for the treatment of Duchenne’s Muscular Dystrophy (DMD).  DMD is an X-chromosome linked neuromuscular progressive disease caused by mutations in the dystrophin gene leading to muscle weakness, most commonly seen in young boys. In the US approximately 15,000 boys are suffering with the disease. Novel gene-based, m-RNA and pharmacological approaches are being developed and show great promise for the treatment of DMD.

“ABL looks forward to continuing to serve the mission of the NIH through this contract with NINDS and embraces the opportunity to work alongside some of the most innovative investigators in the field to develop cutting-edge products that prevent, treat, and cure neurological disorders and rare genetic diseases, like DMD.” said Lauren Hudacik, President and CEO of ABL.

Advanced BioScience Laboratories, Inc

9800 Medical Center Drive, Building D

Rockville, MD 20850

Contact: Timothy R. Fouts, Ph.D.

Phone: 301-816-5453

Email: Timothy.Fouts@ablinc.com